source
- Celldex shares drop as Phase 3 data for barzolvolimab show efficacy but raise anaphylaxis safety concernsCelldex reported Phase 3 results for barzolvolimab in chronic spontaneous urticaria, showing strong efficacy against hives and itching. Two cases of life-threatening anaphylaxis were observed amon…
- Novo aims to increase oral Wegovy manufacturing capacity tenfold by 2030Novo announced at its Capital Markets Day that it plans to expand the manufacturing capacity for its oral GLP-1 drug Wegovy by a factor of ten by the end of the decade. The company said about 1.5…